Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Trizivir.

Philip Keiser1, Naiel Nassar

  • 1University of Texas Southwestern Medical Center, Department of HIV/AIDS Services, Parkland Health and Hospital System, Dallas, Texas, USA.

Expert Opinion on Pharmacotherapy
|May 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A social innovation to empower community-led monitoring and mobilization for HIV prevention in rural Kenya: experimenting to reduce the HIV prevention policy-implementation gap.

Frontiers in public health·2023
Same author

Enabling structural resilience of street-involved children and youth in Kenya: reintegration outcomes and the Flourishing Community model.

Frontiers in psychology·2023
Same author

Flourishing Communities: A new model to promote sustainable community leadership and transformation in semi-rural Kenya.

Journal of community & applied social psychology·2023
Same author

Long COVID and mental health correlates: a new chronic condition fits existing patterns.

Health psychology and behavioral medicine·2023
Same author

Primary and Secondary Attack Rates by Vaccination Status after a SARS-CoV-2 B.1.617.2 (Delta) Variant Outbreak at a Youth Summer Camp-Texas, June 2021.

Journal of the Pediatric Infectious Diseases Society·2022
Same author

Adverse childhood experiences, adult anxiety and social capital among women in rural Kenya.

Journal of anxiety disorders·2022

Trizivir, a triple nucleoside regimen, offers a simpler HIV treatment option with improved adherence and fewer side effects compared to protease inhibitor-based therapies. However, its efficacy may be reduced in patients with very high viral loads.

Area of Science:

  • Infectious Diseases
  • Virology
  • Pharmacology

Background:

  • Traditional HIV treatment involves complex regimens with high pill burdens, often including nucleoside analogues and protease inhibitors (PIs).
  • Alternative regimens, such as triple nucleoside-based therapies, aim to improve patient adherence and reduce toxicities associated with PIs.

Purpose of the Study:

  • To evaluate Trizivir, a fixed-dose combination of zidovudine, lamivudine, and abacavir, as an alternative HIV treatment.
  • To compare the efficacy and tolerability of Trizivir with PI-based regimens.

Main Methods:

  • Review of clinical studies comparing Trizivir to PI-based HIV treatment regimens.
  • Analysis of adherence, toxicity profiles, and viral suppression rates.

Related Experiment Videos

Main Results:

  • Trizivir provides a convenient once-daily dosing schedule, improving adherence and reducing PI-related toxicities like hyperlipidaemia.
  • While generally effective, Trizivir's components showed less potent HIV-1 viral replication suppression than a PI-based regimen in a subset of patients with very high viral loads.
  • A small incidence of hypersensitivity reactions was noted with Trizivir use.

Conclusions:

  • Trizivir represents a valuable option in HIV management due to its simplified dosing and favorable side effect profile.
  • Consideration of Trizivir, alone or in combination, is warranted for HIV therapy, particularly when adherence and PI-associated toxicities are concerns.